4.3 Article

The prevalence of chronic obstructive pulmonary disease in Uppsala, Sweden - the Burden of Obstructive Lung Disease (BOLD) study: cross-sectional population-based study

Journal

CLINICAL RESPIRATORY JOURNAL
Volume 6, Issue 2, Pages 120-127

Publisher

WILEY
DOI: 10.1111/j.1752-699X.2011.00257.x

Keywords

chronic obstructive pulmonary disease; c-reactive protein; forced expiratory volume in 1 second; forced vital capacity; interleukin-6; tuberculosis

Funding

  1. ALTANA
  2. Aventis
  3. AstraZeneca
  4. Boehringer-Ingelheim
  5. Chiesi
  6. GlaxoSmithKline
  7. Merck
  8. Novartis
  9. Pfizer
  10. Schering-Plough
  11. Sepracor
  12. University of Kentucky
  13. Landspitali-University
  14. Astra Zeneca in Iceland
  15. GlaxoSmithKline in Iceland
  16. Swedish Heart and Lung Foundation
  17. Swedish Heart and Lung Association
  18. GlaxoSmithKline, Sweden

Ask authors/readers for more resources

Objectives: To estimate chronic obstructive pulmonary disease (COPD) prevalence in Uppsala and the impact of risk factors on disease prevalence using the standardised methods of the Burden of Obstructive Lung Disease (BOLD) study initiative. Methods: Randomly selected participants, aged 40 years or more (n = 548) responded to a questionnaire regarding smoking habits, respiratory symptoms, medical history, and exposure to airway irritants. Spirometry, with a post-bronchodilator test, was performed and COPD defined as post-bronchodilatory forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) < 0.70 or FEV1/FVC < lower limit of normality (LLN). Circulatory inflammatory markers were measured. Results: COPD prevalence was 16.2%, which was the fourth lowest prevalence of COPD, compared with 12 other BOLD centres. Main risk factors for COPD were increasing age [odds ratio (OR) = 2.08 per 10 years] and smoking (OR = 1.33 per 10 pack years). Higher education was protective (OR = 0.70 per 5 years). Previous tuberculosis was an almost significant risk factor for COPD (P = 0.08). Subjects with COPD reported more respiratory symptoms but only 29% had previous doctor diagnosed COPD, asthma, chronic bronchitis or emphysema. Participants with COPD had higher levels of C-reactive protein (P = 0.01), but no difference was observed in interleukin 6 (IL-6) levels. Using LLN instead of the fixed FEV1/FVC ratio reduced the prevalence of COPD to 10%. Conclusion: COPD prevalence in Uppsala was similar to other BOLD centres in high-income countries. Apart from known COPD risk factors (age, smoking, lower educational level), a history of tuberculosis may be associated with COPD even in high-income countries. COPD remains under-diagnosed, as only 29% of subjects with COPD had a previously diagnosed lung disorder.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available